MitralCord

Company Overview

Snapshot

Founded in June 2012 by Igal Kushnir, MitralCord operated with 1–10 employees. The company secured funding in one round from one investor, The Carel Group. MitralCord ceased operations in December 2019.

Business overview

MitralCord developed a minimally invasive transcatheter-transseptal solution for mitral valve regurgitation, a prevalent heart disease. The company's core product, PureChord, was designed to be performed on a beating heart using standard cardiac procedures and materials, aiming to eliminate the risks associated with open-heart surgery. This approach sought to reduce hospitalization periods and accelerate patient recovery. MitralCord operated within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets, serving healthcare providers, hospitals, and surgeons.

Company Intelligence Q&A

What was MitralCord's primary focus?

MitralCord focused on developing a minimally invasive transcatheter-transseptal solution for mitral valve regurgitation, a common type of heart disease.

Who founded MitralCord?

MitralCord was founded by Igal Kushnir, who also served as Chairman and Medical Director.

What was the operational status of MitralCord?

MitralCord ceased operations in December 2019, making it a non-active entity.

What was the key benefit of MitralCord's solution?

MitralCord's solution aimed to eliminate the risks of open-heart surgery by performing the procedure on a beating heart, leading to minimal hospitalization and faster patient recovery.

In which sector did MitralCord primarily operate?

MitralCord operated within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics.